Evidence map›Paper›PMID 41185726›Full record

ArticleIJU case reports2025

A Case of Metastatic Castration-Resistant Prostate Cancer With

Yusuke Sato, Yoichi Fujii, Masaki Nakamura, Chiharu Tanai, Yuta Yamada, Kousuke Watanabe, Hidenori Kage, Kuniko Sunami, Katsutoshi Oda, Haruki Kume

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yusuke SatoDepartment of Urology, Graduate School of Medicine The University of Tokyo Bunkyo-ku Japan.ORCID https://orcid.org/0000-0002-6239-6050
Yoichi FujiiDepartment of Urology, Graduate School of Medicine The University of Tokyo Bunkyo-ku Japan.
Masaki NakamuraDepartment of Urology NTT Medical Center Tokyo Shinagawa-ku Japan.ORCID https://orcid.org/0000-0002-7473-3325
Chiharu TanaiDepartment of Medical Oncology NTT Medical Center Tokyo Shinagawa-ku Japan.
Yuta YamadaDepartment of Urology, Graduate School of Medicine The University of Tokyo Bunkyo-ku Japan.
Kousuke WatanabeNext-Generation Precision Medicine Development Laboratory, Graduate School of Medicine The University of Tokyo Bunkyo-ku Japan.
Hidenori KageDepartment of Respiratory Medicine, Graduate School of Medicine The University of Tokyo Bunkyo-ku Japan.
Kuniko SunamiDepartment of Laboratory Medicnie National Cancer Center Hospital Chuo-ku Japan.
Katsutoshi OdaDivision of Integrative Genomics, Graduate School of Medicine The University of Tokyo Bunkyo-ku Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine The University of Tokyo Bunkyo-ku Japan.ORCID https://orcid.org/0000-0001-9841-0857

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A certain proportion of prostate cancers have alterations in homologous recombination repair (HRR)- related genes. poly ADP-ribose polymerase (PARP) inhibitors have been approved for metastatic castration-resistant prostate cancer (mCRPC) with mutations in the Case Presentation: The patient was a 59-year-old man with mCRPC. FoundationOne CDx was performed using surgical specimens and detected a pathogenic variant of the Conclusion: Niraparib was effective for mCRPC with Trial Registration: The prospective trial of patient-proposed healthcare services with multiple targeted agents based on the results of gene profiling by multigene panel test (BELIEVE) (NCCH1901/jRCTs031190104).

Indexed as

genomic medicineniraparibpoly (ADP‐ribose) polymerase inhibitorsprecision medicineprostatic neoplasms

Identifiers

PMID41185726
PMCPMC12580008

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.